Kymera Therapeutics

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kymera Therapeutics reports successful 2022, eyes growth through strategic partnerships

Kymera Therapeutics had a successful year, with promising data in multiple programs and a focus on targeted protein degradation.
The company's financial position is strong, with key goals set for 2023, including collaborations and advancing pipeline programs.
Challenges lie in program prioritization, mechanism of action clarity, and optimizing dosing strategies, while opportunities exist in partnerships and therapeutic innovation.
Overall, Kymera's innovative approach and strategic outlook position it well for growth and continued success in 2023.

Kymera Therapeutics reports solid Q1 performance and eyes clinical milestones

Kymera Therapeutics is progressing well in its pipeline development, focusing on innovative programs with broad enrollment criteria.
Financially, the company is stable with a strong cash position and a clear runway into the future.
While facing challenges in capital allocation and program development, Kymera is actively seeking opportunities for growth and collaboration.

Kymera Therapeutics reports robust earnings, advances in clinical trials

Kymera Therapeutics showcased strong financial performance, progress in clinical trials, and a patient-centric approach to drug development.
While facing challenges in clarity on certain trial aspects and partnership limitations, the company is well-positioned for growth and innovation.
Opportunities lie in expanding clinical studies, developing new INDs, and exploring additional indications for their drug portfolio.

Kymera Therapeutics achieves clinical milestones and financial stability for growth

Kymera Therapeutics has made significant progress in clinical development and financial stability, positioning the company for future growth and success.
The company's focus on genetically validated targets, degrader mechanisms, and combination therapies underscores a strategic and innovative approach to drug development.
While facing challenges in dose optimization and safety standards, Kymera has opportunities to leverage its strengths in solid tumors and immunology for therapeutic advancements.
Overall, Kymera's performance, strengths, and opportunities outweigh the challenges, indicating a promising outlook for the company's future in the biopharmaceutical industry.

Kymera Therapeutics reports robust earnings, advances oral immunology pipeline

Kymera Therapeutics is in a strong financial position with a clear runway for growth, focusing on advancing their oral immunology pipeline and strategic partnerships. They face challenges in prioritizing indications but have opportunities for collaborations and innovative therapeutic development.
The company's progress in clinical programs, including dose escalation trials and milestone achievements, reflects their commitment to advancing novel therapies and addressing unmet medical needs in inflammatory diseases, oncology, and immunology.

Kymera Therapeutics reports solid Q1 performance and eyes program expansion

Kymera Therapeutics had a strong start in 2024 with promising program updates and financial stability.
The company's focus on innovative degrader medicines and potential indication expansion positions it for future growth.
Challenges in data disclosure timing and partnership decisions require strategic navigation for sustained success.
Overall, Kymera's performance, strengths, and opportunities indicate a positive trajectory with key milestones ahead.

Kymera Therapeutics reports strong Q2 earnings and eyes CNS expansion

Kymera Therapeutics showcased strong financial performance, progress in clinical trials, and a focus on innovative drug development approaches.
While facing challenges in market competition and financial management, the company is well-positioned to capitalize on growth opportunities.
Overall, Kymera's emphasis on developing effective oral immunology drugs and exploring CNS indications sets a positive trajectory for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Kymera Therapeutics has nine programs in its pipeline. It has a collaboration with Sanofi on its lead therapy IRAK-4.

Why Shares of Kymera Therapeutics Jumped on Tuesday

KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical antitumor activity in patients expected in the fourth quarter of 2023

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

Kymera Therapeutics' valuation is difficult to estimate due to lack of positive net income, making it a poor buy. The company received FDA Orphan Drug Designation for KT-253, a potential treatment for acute myeloid leukemia, boosting its prospects. KYMR's partnership with Sanofi provides significant funding opportunities, but the company's lack of profitability and potential need for capital raises are concerning.

Kymera Therapeutics - Need More Developments Before Making This A Buy

Perella Weinberg Partners (PWP) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants Bruce Jacobs - CFO Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Justine Koenigsberg - VP, IR Conference Call Participants Marc Frahm - TD Cowen Brad Canino - Stifel Chris Shibutani - Goldman Sachs Michael Schmidt - Guggenheim Kalpit Patel - B. Riley Securities Vikram Purohit - Morgan Stanley Eric Joseph - JPMorgan Srikripa Devarakonda - Truist Securities Derek Archila - Wells Fargo Operator Hello and welcome to the Kymera Therapeutics Second Quarter 2023 Quarterly Results Call.

Perella Weinberg Partners (PWP) Q2 2023 Earnings Call Transcript

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.78 per share a year ago.

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates

KT-474/SAR444656 (IRAK4) Phase 2 trials for both hidradenitis suppurativa (HS) and atopic dermatitis (AD)  planned to start in 4Q23 by partner Sanofi

Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update

WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2023 financial results on August 3, 2023, and will host a conference call at 8:30 a.m. ET that day.

Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3

WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KT-253 for the treatment of Acute Myeloid Leukemia (AML).

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor models

Kymera Therapeutics' STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target knockdown in ongoing clinical trials, with no dose limiting toxicities observed Data on additional KT-333 and KT-413 patient cohorts to be shared in conjunction with next week's ICML meeting WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate substantial target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed.

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor (SMI) in preclinical models of ALL and AML A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor (SMI) in preclinical models of ALL and AML

Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company's management team will attend the following upcoming investor event:

Kymera Therapeutics to Participate in Upcoming June Investor Conference

WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer. Dr. Chadwick joins Kymera with extensive experience overseeing global development operations, regulatory and program management at a range of biopharmaceutical companies. As a member of the Company's senior management team, Dr. Chadwick will develop and execute near-term and long-range strategies to maximize the impact of Kymera's expanding pipeline.

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

KT-253 is a novel, highly potent and selective heterobifunctional degrader of the MDM2 oncoprotein with a differentiated profile from small molecule inhibitors in development for the treatment of liquid and solid tumors

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

In the Phase 1 trial, KT-474 showed evidence of robust IRAK4 degradation in blood and skin lesions as well as a systemic anti-inflammatory effect in hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients and was generally well-tolerated

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

PROCEPT BioRobotics Corp

LiveRamp Holdings Inc

Silicon Motion Technology

AbCellera Biologics

Hesai Group

Schrodinger 

While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept some risks.

7 Growth Stocks That Could Double Your Money in 2023

Kymera produced solid-looking phase 1 data, but Pfizer's problems in the space, along with some safety issues, hurt its stock. When partner Sanofi produces phase 2 data, this company will be considerably derisked, assuming the data is clearly positive.

Kymera: More Data Needed

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Bruce Jacobs - Chief Financial Officer Nello Mainolfi - Founder, President and CEO Jared Gollob - Chief Medical Officer Conference Call Participants Michael Schmidt - Guggenheim Brad Canino - Stifel Chris Shibutani - Goldman Sachs Marc Frahm - TD Cowen Mike Kratky - SVB Timur Ivannikov - Raymond James Kalpit Patel - B. Riley Operator Good morning, and welcome to the Kymera Therapeutics First Quarter 2023 Earnings Conference Call [Operator Instructions].

Kymera Therapeutics, Inc. (KYMR) Q1 2023 Earnings Call Transcript

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.71 per share a year ago.

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Misses Revenue Estimates

Phase 1 clinical trial of MDM2 degrader (KT-253) initiated KT-474 (SAR444656) Phase 2 planned to start in 2023; Kymera to present Phase 1 clinical data at EADV Symposium in May Phase 1 trials for STAT3 (KT-333) and IRAKIMiD (KT-413) degraders ongoing, with program updates at ICML in June March 31, 2023 cash balance approximately $516 million, with cash runway into second half of 2025 Company to hold quarterly results call at 8:30 a.m. ET WATERTOWN, Mass.

Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update

WATERTOWN, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report first quarter 2023 financial results on May 4, 2023, and will host a conference call at 8:30 a.m.

Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4

Agios Pharmaceuticals

Amylyx Pharmaceuticals

Xencor

Harmony Biosciences Holdings

Morphic Holding Inc

 Pliant Therapeutics

Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.02 trillion in 2021.

7 Biotech Stocks to Buy for 100% Returns

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Bruce Jacobs - Chief Financial Officer Nello Mainolfi - Founder & Chief Executive Officer Jared Gollob - Chief Medical Officer Conference Call Participants Eric Joseph - JPMorgan Bradley Canino - Stifel Vikram Purohit - Morgan Stanley Paul Jeng - Guggenheim Securities Marc Frahm - Cowen and Company Michael Kratky - SVB Securities Andrew Fleszar - B. Riley Securities Zhiqiang Shu - Berenberg Timur Ivannikov - Raymond James Xiangtian Tan - Jefferies Operator Hello, and welcome to the Kymera Therapeutics Fourth Quarter 2022 Earnings Conference Call.

Kymera Therapeutics, Inc. (KYMR) Q4 2022 Earnings Call Transcript

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.26% and 37.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023

News for Kymera Therapeutics Stock (KYMR)